EANS-Adhoc: SYGNIS Pharma AG / SYGNIS Pharma AG secures further financial resources with shareholder loan

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Capital measures
04.03.2013

Ad hoc-Release according to § 15 WpHG

SYGNIS Pharma AG secures further financial resources with shareholder
loan

Heidelberg 4 March 2013 - SYGNIS Pharma AG (Frankfurt: LIO1; ISIN:
DE000A1RFM03, Prime Standard) today reports on the granting of a
shareholder loan for a total amount of up to EUR 0.7 million by its
main shareholders Genetrix Life Sciences, A.B., Uppsala (Sweden) and
dievini Hopp BioTech holding GmbH & Co. KG, Walldorf (Germany) with
an interest-rate at customary market conditions. As a result this
loan, which is payable on demand and subject to a condition
precedent, secures the financing of SYGNIS' existing operations,
according to the present plans, until mid 2013. The loan is unsecured
and is due for repayment not before the end of 2015.

**** end of ad hoc ****

For further information please contact:

SYGNIS Pharma AG
Peter Willinger
CFO

Tel: +49 6221 454 836
Email: willinger@sygnis.de

### Disclaimer This publication is intended for information only and
constitutes neither an offer to sell nor an invitation to buy
securities. Some statements included in this press release, relating
neither to proven financial results nor other historical data, should
be viewed as forward-looking, i.e. not definite. Such statements are
mainly predictions of future results, trends, plans or goals. These
statements should not be considered to be total guarantees since
given their very nature they are subject to known and unknown risks
and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS
Pharma AG may deviate greatly from the established conclusions or
implied predictions contained in such statements. SYGNIS does not
undertake to publicly update or revise these statements in the light
of new information or future results or for any other reason. ###

Further inquiry note:
Marc Risch
Telefon: +49 (6221) 454 - 737
E-Mail: Marc.Risch@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1RFM03
indexes: CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
Stuttgart, regulated dealing/prime standard: Frankfurt
language: English